Guojin Securities: Innovation and Internationalization Drive Yutong Pharmaceutical Group (01093.HK) with a "Buy" Rating

According to the Wise Finance APP, Guojin Securities released a research report stating that Shiyao Group (01093.HK) is a leading comprehensive pharmaceutical company in China, with business covering formulations (generic drugs + innovative drugs), raw materials, and functional food sectors, with a solid operating foundation. It has deep research and development capabilities, with the effects of innovative transformation highlighted, and its internationalization and commercialization achievements are industry-leading. The bank expects its net profit attributable to shareholders for the years 2026-2028 to be 7.932/6.328/6.704 billion yuan, corresponding to PEs of 9.08/11.38/10.74 times. The company is given a 15 times PE valuation for 2026, with a target market value of approximately 119 billion yuan (137.9 billion Hong Kong dollars), and a "buy" rating is given.